China
Reistone Biopharma is a clinical stage biopharmaceutical company founded in 2018. The company's slogan "Focusing on rapidly developing innovative medicines through global collaborations within Research and Development" underlines its commitment to developing novel medicines for life-threatening autoimmune diseases. With a primary focus on biotechnology and pharmaceuticals, Reistone is dedicated to addressing significant unmet medical needs in China and globally.
Reistone's approach to developing therapies for diseases emphasizes the importance of strong collaboration between scientists, industry, regulators, and patient groups. This collaborative approach is evident in the company's close partnerships with key stakeholders and leading pharmaceutical companies. Their efforts have led to the forging of global collaborations aimed at transforming new biotechnology insights into breakthrough medicines for autoimmune diseases.
The company recently secured a significant $100.00M Series A investment on 09 May 2022. Notable investors in this round include Hanne Capital, Huagai Capital, Yunion Health Investments, Zero2IPO Ventures, Shanghai Zhangjiang Haocheng Venture Capital, Shodu Healthcare Fund, and Capital Healthcare Fund.
Overall, Reistone Biopharma's innovative approach to drug development, strong industry collaborations, and recent substantial investment reflect the company's potential for addressing critical unmet medical needs and making a significant impact in the biopharmaceutical industry.
